294 related articles for article (PubMed ID: 21474670)
1. Integrin β7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion.
Neri P; Ren L; Azab AK; Brentnall M; Gratton K; Klimowicz AC; Lin C; Duggan P; Tassone P; Mansoor A; Stewart DA; Boise LH; Ghobrial IM; Bahlis NJ
Blood; 2011 Jun; 117(23):6202-13. PubMed ID: 21474670
[TBL] [Abstract][Full Text] [Related]
2. Role of Myeloma-Derived MIF in Myeloma Cell Adhesion to Bone Marrow and Chemotherapy Response.
Zheng Y; Wang Q; Li T; Qian J; Lu Y; Li Y; Bi E; Reu F; Qin Y; Drazba J; Hsi E; Yang J; Cai Z; Yi Q
J Natl Cancer Inst; 2016 Nov; 108(11):. PubMed ID: 27381622
[TBL] [Abstract][Full Text] [Related]
3. Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma.
Noborio-Hatano K; Kikuchi J; Takatoku M; Shimizu R; Wada T; Ueda M; Nobuyoshi M; Oh I; Sato K; Suzuki T; Ozaki K; Mori M; Nagai T; Muroi K; Kano Y; Furukawa Y; Ozawa K
Oncogene; 2009 Jan; 28(2):231-42. PubMed ID: 18850009
[TBL] [Abstract][Full Text] [Related]
4. In vitro migratory aberrancies of mesenchymal stem cells derived from multiple myeloma patients only partially modulated by bortezomib.
Xu X; Yang J; Tang Y; Li J; Zhu Y; Lu H; Fei X
Int J Clin Exp Pathol; 2014; 7(10):6705-15. PubMed ID: 25400750
[TBL] [Abstract][Full Text] [Related]
5. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy.
Azab AK; Runnels JM; Pitsillides C; Moreau AS; Azab F; Leleu X; Jia X; Wright R; Ospina B; Carlson AL; Alt C; Burwick N; Roccaro AM; Ngo HT; Farag M; Melhem MR; Sacco A; Munshi NC; Hideshima T; Rollins BJ; Anderson KC; Kung AL; Lin CP; Ghobrial IM
Blood; 2009 Apr; 113(18):4341-51. PubMed ID: 19139079
[TBL] [Abstract][Full Text] [Related]
6. Sphingosine-1-phosphate activates chemokine-promoted myeloma cell adhesion and migration involving α4β1 integrin function.
García-Bernal D; Redondo-Muñoz J; Dios-Esponera A; Chèvre R; Bailón E; Garayoa M; Arellano-Sánchez N; Gutierrez NC; Hidalgo A; García-Pardo A; Teixidó J
J Pathol; 2013 Jan; 229(1):36-48. PubMed ID: 22711564
[TBL] [Abstract][Full Text] [Related]
7. Caveolin-1 is required for vascular endothelial growth factor-triggered multiple myeloma cell migration and is targeted by bortezomib.
Podar K; Shringarpure R; Tai YT; Simoncini M; Sattler M; Ishitsuka K; Richardson PG; Hideshima T; Chauhan D; Anderson KC
Cancer Res; 2004 Oct; 64(20):7500-6. PubMed ID: 15492276
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma.
Hurt EM; Wiestner A; Rosenwald A; Shaffer AL; Campo E; Grogan T; Bergsagel PL; Kuehl WM; Staudt LM
Cancer Cell; 2004 Feb; 5(2):191-9. PubMed ID: 14998494
[TBL] [Abstract][Full Text] [Related]
9. CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells.
Tai YT; Soydan E; Song W; Fulciniti M; Kim K; Hong F; Li XF; Burger P; Rumizen MJ; Nahar S; Podar K; Hideshima T; Munshi NC; Tonon G; Carrasco RD; Afar DE; Anderson KC
Blood; 2009 Apr; 113(18):4309-18. PubMed ID: 19196658
[TBL] [Abstract][Full Text] [Related]
10. Acquisition of resistance toward HYD1 correlates with a reduction in cleaved α4 integrin expression and a compromised CAM-DR phenotype.
Emmons MF; Gebhard AW; Nair RR; Baz R; McLaughlin ML; Cress AE; Hazlehurst LA
Mol Cancer Ther; 2011 Dec; 10(12):2257-66. PubMed ID: 21980133
[TBL] [Abstract][Full Text] [Related]
11. Binding of MMP-9-degraded fibronectin to β6 integrin promotes invasion via the FAK-Src-related Erk1/2 and PI3K/Akt/Smad-1/5/8 pathways in breast cancer.
Li W; Liu Z; Zhao C; Zhai L
Oncol Rep; 2015 Sep; 34(3):1345-52. PubMed ID: 26134759
[TBL] [Abstract][Full Text] [Related]
12. Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia.
Yanamandra N; Colaco NM; Parquet NA; Buzzeo RW; Boulware D; Wright G; Perez LE; Dalton WS; Beaupre DM
Clin Cancer Res; 2006 Jan; 12(2):591-9. PubMed ID: 16428505
[TBL] [Abstract][Full Text] [Related]
13. Alkylating agents induce activation of NFkappaB in multiple myeloma cells.
Baumann P; Mandl-Weber S; Oduncu F; Schmidmaier R
Leuk Res; 2008 Jul; 32(7):1144-7. PubMed ID: 18083229
[TBL] [Abstract][Full Text] [Related]
14. Loss of beta1-integrin enhances TGF-beta1-induced collagen expression in epithelial cells via increased alphavbeta3-integrin and Rac1 activity.
Hayashida T; Jones JC; Lee CK; Schnaper HW
J Biol Chem; 2010 Oct; 285(40):30741-51. PubMed ID: 20650890
[TBL] [Abstract][Full Text] [Related]
15. Evidence that β7 Integrin Regulates Hematopoietic Stem Cell Homing and Engraftment Through Interaction with MAdCAM-1.
Murakami JL; Xu B; Franco CB; Hu X; Galli SJ; Weissman IL; Chen CC
Stem Cells Dev; 2016 Jan; 25(1):18-26. PubMed ID: 26422691
[TBL] [Abstract][Full Text] [Related]
16. Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with beta 1 integrin- and phosphatidylinositol 3-kinase-dependent PKC alpha activation.
Podar K; Tai YT; Lin BK; Narsimhan RP; Sattler M; Kijima T; Salgia R; Gupta D; Chauhan D; Anderson KC
J Biol Chem; 2002 Mar; 277(10):7875-81. PubMed ID: 11751905
[TBL] [Abstract][Full Text] [Related]
17. Suitable drug combination with bortezomib for multiple myeloma under stroma-free conditions and in contact with fibronectin or bone marrow stromal cells.
Kikuchi J; Koyama D; Mukai HY; Furukawa Y
Int J Hematol; 2014 Jun; 99(6):726-36. PubMed ID: 24706190
[TBL] [Abstract][Full Text] [Related]
18. Targeting phospho-MARCKS overcomes drug-resistance and induces antitumor activity in preclinical models of multiple myeloma.
Yang Y; Chen Y; Saha MN; Chen J; Evans K; Qiu L; Reece D; Chen GA; Chang H
Leukemia; 2015 Mar; 29(3):715-26. PubMed ID: 25179733
[TBL] [Abstract][Full Text] [Related]
19. Reelin promotes the adhesion and drug resistance of multiple myeloma cells via integrin β1 signaling and STAT3.
Lin L; Yan F; Zhao D; Lv M; Liang X; Dai H; Qin X; Zhang Y; Hao J; Sun X; Yin Y; Huang X; Zhang J; Lu J; Ge Q
Oncotarget; 2016 Mar; 7(9):9844-58. PubMed ID: 26848618
[TBL] [Abstract][Full Text] [Related]
20. Integrin β5 contributes to the tumorigenic potential of breast cancer cells through the Src-FAK and MEK-ERK signaling pathways.
Bianchi-Smiraglia A; Paesante S; Bakin AV
Oncogene; 2013 Jun; 32(25):3049-58. PubMed ID: 22824793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
